MLANA and neoplasm: TCR therapy trials have mostly targeted overexpressed self/tumor antigens that are also expressed by healthy adult cells, such as gp100 and Melan-A/MART-1, or oncofetal antigens that are present on healthy cells exclusively during fetal development and are ectopically expressed in tumors, such as melanoma antigen E or NY-ESO-1 [169].